Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.
You may also be interested in...
After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.
Creabilis Pulls In Corporate VC With €15M Series B
Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.
Creabilis Pulls In Corporate VC With €15M Series B
Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.